The novel anti-epileptic drug stiripentol (Diacomit) has been recommended for PBS listing in the treatment of severe myoclonic epilepsy in infancy, also known as Dravet syndrome. At its March meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the drug be subsidised on the PBS as adjuvant treatment of patients with generalised clonic and tonic-clonic seizures ...
Novel anti-epileptic drug gets PBS recommendation for Dravet syndrome
By Michael Woodhead
7 May 2020